

# POSTER PRESENTATIONS

THURSDAY, OCT. 29  
3:45-4:15P

|                                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patient-Reported Outcome Results From the Beamion LUNG-1 Trial in Treatment-Naïve Patients With Human Epidermal Growth Factor Receptor 2-Mutant Advanced Non-Small Cell Lung Cancer                            |
| Phagophobia in Oral Anticancer Medication Management: Utilizing NCODA Resources in Irish Oncology Clinical Practice                                                                                            |
| Prostate-Specific Antigen Outcomes of Darolutamide and Androgen Deprivation Therapy in Patient Subgroups by Age, Comorbidities, and Concomitant Medications: ARANOTE Post Hoc Analyses                         |
| SOHO-01: Updated Safety and Efficacy of Sevabertinib in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Mutant Non-Small Cell Lung Cancer                                                      |
| Patient-Reported Outcomes and Health-Related Quality of Life in Patients With Advanced ROS1-Positive Non-Small Cell Lung Cancer Treated With Zidesamtinib: ARROS-1 Phase 2 Trial Data                          |
| Real-World Evidence on Eflapegrastim: Global Demographics and Clinical Outcomes in General Oncology Practice                                                                                                   |
| Real-World Patient Characteristics, Treatment Patterns, and Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer: Insights by Phosphatase and Tensin Homolog Status                                |
| Health-Related Quality of Life in Patients Previously Treated With an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor From HARMONi: A Phase 3 Trial of Ivonescimab Versus Placebo Plus Chemotherapy |
| Pharmacist-Led Quality Improvement Project to Optimize Abemaciclib Dosing Within a Community Oncology Network                                                                                                  |
| Docetaxel Plus Albumin Formulation for Breast Cancer Treatment                                                                                                                                                 |
| Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab Versus Daratumumab-Based Triplets in Relapsed/Refractory Multiple Myeloma: MajesTEC-3 Post Hoc Analysis              |
| New York Oncology Hematology Development and Implementation of Outpatient Bispecific Antibody Therapy Program                                                                                                  |
| Advancing Global Learning in Oncology Through International Collaboration: NCODA’s Global Congress                                                                                                             |
| Real-World Outcomes With Early Adoption of Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review                                                |
| Understanding Cancer Immuno-Oncology: Lessons From Developing an Educational Program on Clinical Trial Design and Immunotherapy                                                                                |
| Ovarian Cancer Awareness. The Good? The Bad, and the Ugly. Where Are We Now?                                                                                                                                   |
| Safety and Feasibility of Concurrent Vorasidenib and Folinic Acid, Fluorouracil, and Oxaliplatin in Progressive Isocitrate Dehydrogenase-Mutant Astrocytoma in the Setting of Dual Active Malignancies         |
| Financial Toxicity New Face: How Medicaid Unwinding, Insurance Changes, and Rising Cost of Living Are Reshaping Cancer Care                                                                                    |

SCREEN

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18